Trials / Completed
CompletedNCT00601731
Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months
A Phase 2, Open-label, Controlled, Multi-center Study to Evaluate Meningococcal ACWY Antibody Response in Children Aged 40 and 60 Months Who Have Previously Received Novartis MenACWY Conjugate Vaccine as Infants
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 382 (actual)
- Sponsor
- Novartis Vaccines · Industry
- Sex
- All
- Age
- 40 Months – 63 Months
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate how well the immuno response against meningococcal serogroups A, C, W and Y lasts in children who were vaccinated with MenACWY as infants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MenACWY-CRM197 | Blood test, 40-months and 60-months children |
| BIOLOGICAL | Blood test | Blood test, 40-months and 60-months children |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2010-07-01
- Completion
- 2010-09-01
- First posted
- 2008-01-28
- Last updated
- 2014-10-24
- Results posted
- 2012-09-19
Locations
3 sites across 2 countries: Canada, United Kingdom
Source: ClinicalTrials.gov record NCT00601731. Inclusion in this directory is not an endorsement.